Benchmarking di-Higgs production in various extended Higgs sector models

We present a comprehensive study on Higgs pair production in various archetypical extended Higgs sectors such as the real and the complex 2-Higgs-Doublet Model, the 2-Higgs-Doublet Model augmented by a real singlet field and the Next-to-Minimal Supersymmetric extension of the Standard Model. We take into account all relevant theoretical and experimental constraints, in particular the experimental limits on non-resonant and resonant Higgs pair production. We present the allowed cross sections for Standard Model (SM)-like Higgs pair production and the ranges of the SM-like Yukawa and trilinear Higgs self-coupling that are still compatible with the applied constraints. Furthermore, we give results for the pair production of a SM-like with a non-SM-like Higgs boson and for the production of a pair of non-SM-like Higgs bosons. We find that di-Higgs production in the models under investigation can exceed the SM rate substantially, not only in the non-resonance region but also due to resonant enhancement. We give several benchmarks with interesting features such as large cross sections, the possibility to test CP violation, Higgs-to-Higgs cascade decays or di-Higgs production beating single Higgs production. In all of our benchmark points, the next-to-leading order QCD corrections are included in the large top-mass limit. For these points, we found that, depending on the model and the Higgs pair final state, the corrections increase the leading order cross section by a factor of 1.79 to 2.24. We also discuss the relation between the description of Higgs pair production in an effective field theory approach and in the specific models investigated here

Benchmarking di-Higgs production in various extended Higgs sector models

We present a comprehensive study on Higgs pair production in various archetypical extended Higgs sectors such as the real and the complex 2-Higgs-Doublet Model, the 2-Higgs-Doublet Model augmented by a real singlet field and the Next-to-Minimal Supersymmetric extension of the Standard Model. We take into account all relevant theoretical and experimental constraints, in particular the experimental limits on non-resonant and resonant Higgs pair production. We present the allowed cross sections for Standard Model (SM)-like Higgs pair production and the ranges of the SM-like Yukawa and trilinear Higgs self-coupling that are still compatible with the applied constraints. Furthermore, we give results for the pair production of a SM-like with a non-SM-like Higgs boson and for the production of a pair of non-SM-like Higgs bosons. We find that di-Higgs production in the models under investigation can exceed the SM rate substantially, not only in the non-resonance region but also due to resonant enhancement. We give several benchmarks with interesting features such as large cross sections, the possibility to test CP violation, Higgs-to-Higgs cascade decays or di-Higgs production beating single Higgs production. In all of our benchmark points, the next-to-leading order QCD corrections are included in the large top-mass limit. For these points, we found that, depending on the model and the Higgs pair final state, the corrections increase the leading order cross section by a factor of 1.79 to 2.24. We also discuss the relation between the description of Higgs pair production in an effective field theory approach and in the specific models investigated hereinfo:eu-repo/semantics/publishedVersio

Cystic Fibrosis in Egyptian Children: Achievements and Future Directions

Cystic fibrosis (CF) is the most common potentially lethal and life-shortening genetic disease caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Clinical consequences of the CFTR defect are site-specific and range from severe (lungs, pancreas, male reproductive tract) to mild (intestine) to asymptomatic (sweat glands). In many developing countries CF has remained largely unrecognized, and inadequately managed, resulting in avoidable death or suffering in infancy, childhood, and adulthood. Delivering adequate CF services is met by substantial difficulties as the spectrum and distribution of CF in Egypt are still not well known. Against this background, the aim of this work is to emphasize the challenges facing initiation of a CF center in low privileged settings with the objectives of improving diagnosis, survival, and to eventually provide optimum management. Strategies for the implementation and development of CF services, as well as proper collection and documentation of patient data are therefore of vital importance. The characterization of the prevalence and molecular genetics of CF in Egypt is of utmost importance so that appropriate genetic counseling to CF patients and their families can be achieved and to pave the way for new treatment modalities

Essential Medicines at the National Level : The Global Asthma Network's Essential Asthma Medicines Survey 2014

Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013-2020 sets an 80% target for essential NCD medicines' availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013-2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system's capacity to address NCDs.Peer reviewe

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century

Quantum supergroup structure of 1+1-dimensional quantum super-plane, its dual and its differential calculus

Consiglio Nazionale delle Ricerche - Biblioteca Centrale - P.le Aldo Moro, 7 Rome / CNR - Consiglio Nazionale delle RichercheSIGLEITItal